Tevimbra

mountain climb steep cliff climber struggle

Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF

If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.

Angus Liu May 27, 2026 11:25am

FDA chides BeOne, ImmunityBio in separate untitled letters

Jan 15, 2026 11:50am

Jazz touts Ziihera as HER2 agent of choice in stomach cancer

Jan 6, 2026 3:25pm

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am

FDA limits Keytruda, Opdivo uses in stomach cancer

Jun 9, 2025 10:50am

Akeso's fast-rising ivonescimab scores 3rd lung cancer trial win

Apr 23, 2025 11:30am